Nakagawa H, et al. - In adults with moderate to severe atopic dermatitis, experts analyzed the efficacy and safety profile of a topical Janus Kinase (JAK) inhibitor, JTE-052 compared with the vehicle on its own and with 0.1% tacrolimus ointment. It was determined that the patients using the 3% concentration of JAK inhibitor exhibited 73% improvement in the Eczema Area and Severity Score compared with 12% using the placebo (vehicle) ointment. Therefore, the topical use of JAK inhibitor was discovered to be efficacious for treating atopic dermatitis.